Earnings Summary

Praxis Precision Medicines I’s revenue jumped +Inf% since last year same period to $0.52Mn in the Q4 2023. On a quarterly growth basis, Praxis Precision Medicines I has generated 10.04% jump in its revenue since last 3-months.

Praxis Precision Medicines I’s net profit jumped 34.27% since last year same period to $-26.88Mn in the Q4 2023. On a quarterly growth basis, Praxis Precision Medicines I has generated -9.12% fall in its net profits since last 3-months.

Praxis Precision Medicines I’s net profit margin jumped NaN% since last year same period to -5219.03% in the Q4 2023. On a quarterly growth basis, Praxis Precision Medicines I has generated 0.84% jump in its net profit margins since last 3-months.

Praxis Precision Medicines I’s earning per share (EPS) estimates for the current quarter stand at -2.07 - a 34.91% jump from last quarter’s estimates.

Praxis Precision Medicines I’s earning per share (EPS) estimates for the current year stand at -2.07.

Praxis Precision Medicines I’s earning per share (EPS) fell -241.38% since last year same period to -2.97 in the Q4 2023. This indicates that the Praxis Precision Medicines I has generated -241.38% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Praxis Precision Medicines I’s return on assets (ROA) stands at -0.78.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Praxis Precision Medicines I’s return on equity (ROE) stands at -1.69.